Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen

Antimicrobial Agents and Chemotherapy
Adeola OkoduwaYanina Dubrovskaya

Abstract

Nephrotoxicity is a known adverse effect of polymyxin B (PMB). Animal data suggest that once-daily dosing may reduce the rate and delay the onset of acute kidney injury (AKI). In a multicenter retrospective study, we evaluated adult patients with a creatinine clearance (CrCl) of ≥30 ml/min who received ≥48 h of PMB therapy. The primary endpoint was the difference in rate of AKI comparing once- and twice-daily PMB dosing. The secondary endpoints included the time to AKI and the recovery of renal function. Of 273 eligible patients, 100 from each group were matched on the basis of propensity scores. In the matched groups, nephrotoxicity, defined according to risk, injury, failure, loss, and end-stage renal disease (RIFLE) criteria, was more frequent with once- than with twice-daily dosing (47% versus 17%, respectively; P = 0.0005). After adjusting for residual differences by multivariate conditional logistic regression, once-daily dosing was more likely to result in nephrotoxicity (adjusted odds ratio, 2.5; 95% confidence interval [CI], 1.413 to 4.541; P = 0.002). Among 64 patients who developed AKI, the median onsets were similar between the groups (7 days with once versus 6 days with twice-daily dosing, P = 0.095). Of 37 patient...Continue Reading

References

Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Aug 18, 2004·Critical Care : the Official Journal of the Critical Care Forum·Rinaldo BellomoUNKNOWN Acute Dialysis Quality Initiative workgroup
Aug 30, 2005·Antimicrobial Agents and Chemotherapy·Vincent H TamRussell E Lewis
Jan 9, 2008·Antimicrobial Agents and Chemotherapy·Stephanie J WallaceJohn D Turnidge
Feb 14, 2012·The Journal of Infection·Christine J KubinMichael T Yin
Mar 8, 2012·The Annals of Pharmacotherapy·Diana EsaianJohn Papadopoulos
Jun 13, 2012·Antimicrobial Agents and Chemotherapy·Kamilia AbdelraoufVincent H Tam
Aug 22, 2012·Antimicrobial Agents and Chemotherapy·Kamilia AbdelraoufVincent H Tam
Jan 31, 2013·Intensive Care Medicine·R P DellingerUNKNOWN Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup
May 24, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ana M SandriAlexandre P Zavascki
Jul 11, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Darowan S AkajagborBruce L Gilliam
Apr 16, 2014·Antimicrobial Agents and Chemotherapy·Kamilia AbdelraoufVincent H Tam
Oct 1, 2014·Pharmacotherapy·Julie Ann Justo, John A Bosso
Nov 8, 2014·The Journal of Antimicrobial Chemotherapy·Bo YunJian Li
Feb 6, 2015·The Journal of Antimicrobial Chemotherapy·Yanina DubrovskayaVincent H Tam
Aug 18, 2016·PloS One·Maria de Fátima Fernandes VattimoFernanda Teixeira Borges
Nov 2, 2016·Antimicrobial Agents and Chemotherapy·Visanu ThamlikitkulVincent H Tam
Dec 21, 2016·Antimicrobial Agents and Chemotherapy·Alexandre P Zavascki, Roger L Nation
Feb 6, 2017·Behaviour Research and Therapy·Jaehoon Lee, Todd D Little

❮ Previous
Next ❯

Citations

Apr 12, 2019·The Annals of Pharmacotherapy·Yarelis Alvarado ReyesWilliam R Wolowich
Feb 20, 2020·Antimicrobial Agents and Chemotherapy·Jiajun LiuMarc H Scheetz
Mar 17, 2019·Antibiotics·Roger L NationAlexandre P Zavascki
Oct 28, 2019·International Journal of Clinical Pharmacy·Anahid Nourian, Mona Kargar
Dec 29, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Florian WagenlehnerJason M Pogue
Jan 14, 2021·International Journal of Clinical Pharmacy·Jiali ZhangHaibin Dai
Dec 5, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Mekonnen SisayAbraham Nigussie Mekuria
Feb 25, 2021·Drug Design, Development and Therapy·Wenrui SunGuanyang Lin

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.